2-(3,4-二氯苯基)-哌嗪 | 185110-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-(3,4-二氯苯基)-哌嗪
• 中文别名: 2-(3,4-二氯苯基)哌嗪化合物
• 英文名称: 2-(3,4-dichlorophenyl)piperazine
• CAS: 185110-06-9
• 化学式: C₁₀H₁₂Cl₂N₂
• 分子量: 231.125
• InChiKey: PUJZPGUYDJGSAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.23
• 重原子数：
  14.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  24.06
• 氢给体数：
  2.0
• 氢受体数：
  2.0

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-(3,4-二氯苯基)-哌嗪 生成 2-(R,S)-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine
  参考文献：
  名称：

  Spiro-substituted azacyclic-substituted piperazino derivatives as

  摘要：

  该发明涉及以下结构的化合物：##STR1##其中Z、R.sub.c、y、m、u、Ar.sub.2、n、X、R.sub.c'、I和Ar.sub.2如本文所述。这些化合物是神经激肽拮抗剂。这些化合物在治疗慢性气道疾病如哮喘中是有用的。

  公开号：

  US05783579A1
• 作为产物：
  描述：

  3-(3,4-二氯苯基)哌嗪-2-酮 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 2-(3,4-二氯苯基)-哌嗪
  参考文献：
  名称：

  Synthesis and NK1/NK2 binding activities of a series of diacyl-substituted 2-arylpiperazines

  摘要：

  The synthesis and binding affinity for hNK(1) and hNK(2) receptors of a series of diacyl substituted 2-aryl piperazines are described. SAR evaluation led to the racemic derivative 11g as an apparent dual inhibitor. Chiral chromatographic separation of 11g led to the observation that NK1 activity was shown by one enantiomer (13a) and NK2 activity was shown by the other enantiomer (13b). X-ray crystallographic analysis of the crystalline di-BOC derivative of the NK2, active piperazine (15) showed that the 2R configuration was associated with NK2 activity. Further derivatization indicated that dual NK1/NK2 activity could be built into the 2R series. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00645-5

文献信息

• Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors
  作者：Yoshihiro Usui、Fumiaki Uehara、Shinsuke Hiki、Kazutoshi Watanabe、Hiroshi Tanaka、Aya Shouda、Satoshi Yokoshima、Keiichi Aritomo、Takashi Adachi、Kenji Fukunaga、Shinji Sunada、Mika Nabeno、Ken-Ichi Saito、Jun-ichi Eguchi、Keiji Yamagami、Shouichi Asano、Shinji Tanaka、Satoshi Yuki、Narihiko Yoshii、Masatake Fujimura、Takashi Horikawa

  DOI：10.1016/j.bmcl.2017.06.078

  日期：2017.8

  We herein describe the results of further evolution of glycogen synthase kinase (GSK)-3β inhibitors from our promising compounds containing a 2-phenylmorpholine moiety. Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3β inhibitors. SAR studies focused on the phenyl moiety revealed that a 4-fluoro-2-methoxy group afforded potent inhibitory activity toward GSK-3β

  我们在本文中描述了糖原合酶激酶（GSK）-3β抑制剂从含有2-苯基吗啉部分的有希望的化合物中进一步进化的结果。吗啉部分转化为哌嗪部分会产生有效的GSK-3β抑制剂。专注于苯基部分的SAR研究表明，4-氟-2-甲氧基对GSK-3β具有有效的抑制活性。基于对接研究，已表明哌嗪部分的氮原子与Gln185主链的氧原子之间存在新的氢键，与相应的苯吗啉类似物相比，这可能有助于增加活性。还讨论了苯基哌嗪部分的立体化学作用。
• Piperazino derivatives as neurokinin antagonists
  申请人：Schering Corporation

  公开号：US05968929A1

  公开（公告）日：1999-10-19

  The invention relates to compounds of the formula ##STR1## wherein Z, R.sub.c, y, m, u, Ar.sub.2, n, X, R.sub.c', l and Ar.sub.2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.

  该发明涉及公式##STR1##中的化合物，其中Z、R.sub.c、y、m、u、Ar.sub.2、n、X、R.sub.c'、l和Ar.sub.2如本文所述。这些化合物是神经激肽拮抗剂。这些化合物在治疗慢性气道疾病如哮喘方面是有用的。
• Piperazino derivatives as neurokinn antagonists
  申请人：Schering Corporation

  公开号：US05795894A1

  公开（公告）日：1998-08-18

  The invention relates to compounds of the formula ##STR1## These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.

  该发明涉及公式为##STR1##的化合物。这些化合物是神经激肽拮抗剂。这些化合物在治疗慢性气道疾病如哮喘方面具有用途。
• [EN] 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMIDE D'ACIDE 6-(4-HYDROXYPHÉNYL)-3-ALKYL-1H-PYRAZOLO[3,4-B] PYRIDINE-4-CARBOXYLIQUE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：SANOFI SA

  公开号：WO2013045413A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula (I), in which R1, R2, R3, R4, R5, R6 and R7 are defined as indicated below. The compounds of the formula (I) are protein kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式(I)的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式(I)的化合物是蛋白激酶C（PKC）抑制剂，并且对于治疗与糖尿病和糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病和糖尿病视网膜病变等，非常有用。此外，本发明还涉及使用该式化合物，特别是作为药物中的活性成分，以及包含它们的制药组合物。
• [EN] PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS<br/>[FR] DERIVES DE PIPERAZINO ANTAGONISTES DE LA NEUROKININE
  申请人：SCHERING CORPORATION

  公开号：WO1997008166A1

  公开（公告）日：1997-03-06

  (EN) The invention relates to compounds of formula (I) wherein Z, Rc, y, m, u, Ar2, n, X, Rc',(I) and Ar2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.(FR) Composés de formule (I), dans laquelle Z, Rc, y, m, u, Ar2, n, X, Rc', (I) et Ar2 sont conformes aux spécifications du dossier. Ces composés sont des antagonistes de la neurokinine, utiles au traitement de maladies chroniques des voies respiratoires telles que l'asthme.

  该发明涉及公式（I）中的化合物，其中Z，Rc，y，m，u，Ar2，n，X，Rc'，（I）和Ar2如本文所述。这些化合物是神经激肽拮抗剂，可用于治疗慢性呼吸道疾病，如哮喘。